Publications
Detailed Information
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, SH | - |
dc.contributor.author | Bang, SM | - |
dc.contributor.author | Cho, EK | - |
dc.contributor.author | Baek, JH | - |
dc.contributor.author | Oh, JH | - |
dc.contributor.author | Im, SA | - |
dc.contributor.author | Park, YS | - |
dc.contributor.author | Shin, DB | - |
dc.contributor.author | Lee, JH | - |
dc.date.accessioned | 2010-01-11T07:05:32Z | - |
dc.date.available | 2010-01-11T07:05:32Z | - |
dc.date.created | 2021-11-23 | - |
dc.date.created | 2021-11-23 | - |
dc.date.issued | 2004-08 | - |
dc.identifier.citation | Oncology, Vol.66 No.5, pp.353-357 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.other | 148308 | - |
dc.identifier.uri | https://hdl.handle.net/10371/29353 | - |
dc.description.abstract | Objective: The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma. Methods: Patients with histologically proven advanced colorectal adenocarcinoma received a first-line chemotherapy with irinotecan 240 mg/ m(2) on day 1 and capecitabine 2,000 mg/m(2)/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest. Treatment was repeated every 3 weeks. Results: Thirty-nine patients were registered, and 36 were assessable for responses. Sixteen objective responses (44%) were observed with a median response duration of 6.9 months. Stable disease was documented in 14 cases (39%). The median time to progression was 6.7 months. The median overall survival was not reached at the time of analysis, and the 1-year survival rate was 67%. Two patients died: 1 due to sepsis not complicating myelosuppression, and 1 patient, known as a hepatitis B virus carrier prior to chemotherapy, died of hepatic failure, the cause of which was not clinically verified. Frequently encountered therapy-related events were leukopenia and gastrointestinal side effects including diarrhea. Severe hand-and-foot syndrome was observed in only 1 patient. Conclusions: The combination chemotherapy of irinotecan and capecitabine is an active and tolerable regimen for advanced colorectal adenocarcinoma, but the observed deaths suggest a future randomized trial that requires a cautious patient selection. Copyright (C) 2004 S. Karger AG, Basel. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | S. Karger AG | - |
dc.title | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1159/000079482 | - |
dc.citation.journaltitle | Oncology | - |
dc.identifier.wosid | 000223980500003 | - |
dc.identifier.scopusid | 2-s2.0-4444351107 | - |
dc.citation.endpage | 357 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 353 | - |
dc.citation.volume | 66 | - |
dc.identifier.sci | 000223980500003 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, SA | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ORAL FLUOROPYRIMIDINE CARBAMATE | - |
dc.subject.keywordPlus | INTRAVENOUS FLUOROURACIL | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | CONTINUOUS-INFUSION | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | FAILURE | - |
dc.subject.keywordAuthor | colorectal cancer, chemotherapy | - |
dc.subject.keywordAuthor | irinotecan | - |
dc.subject.keywordAuthor | capecitabine | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.